IRIDEX Corporation (IRIX) Earnings Call Transcript
August 18, 2026
Earnings Call Speaker Segments
Thanks, Operator, and I appreciate everyone being with us this afternoon. Joining me today are Patrick Mercer, who serves as IRIDEX's Chief Executive Officer, and Romeo Dizon, our Chief Financial Officer. Earlier today, IRIDEX put out a press release covering our financial results for the quarter that wrapped up on July 4, 2026, and you can find it in the investor section of our website. Before we get going, I want to remind you that during this call, management will be making statements that fall under the forward-looking category as defined by federal securities laws, and these are being made under the safe harbor protections of the Private Securities Litigation Reform Act of 1995. Any statement on this call that isn't a statement of historical fact — including, without limitation, statements about our strategic goals and priorities, matters relating to product development, sales trends, and the markets where we operate. Every forward-looking statement rests on our current estimates and a range of assumptions. Such statements carry material risks and uncertainties that could lead actual results or events to differ materially from what those forward-looking statements anticipate or imply. So you shouldn't rely on these statements; if you want a discussion of the risks and uncertainties tied to our business, please refer to the most recent Form 10-K and Form 10-Q filings with the SEC. Except where the law requires it, IRIDEX disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 18, 2026. With that, I'll hand the call over to Patrick.
Good afternoon, everyone, and thanks for being with us on the call for our second quarter. If there's a single takeaway I'd like to give you today, it's this: IRIDEX has arrived at a significant inflection point where its financial profile is concerned. During the second quarter, we produced positive cash flow, which shows the substantial progress achieved across the past two years in fundamentally transforming how our costs are structured, bolstering the management of working capital, and building a business that is more disciplined and sustainable. As one element of our work to further boost the efficiency of the business, this month we kicked off the process of moving our headquarters. This cost-cutting step has been anticipated for a long time and forms a key piece of our wider push to optimize how our costs are structured, boost operational efficiency, and bring our infrastructure into line with the business we are building for the future. The headquarters relocation will call for a new registration process as well as management of global registration blackout periods. To safeguard our international supply chain and shield top-line distributor revenue streams throughout the transition, we are currently building safety stock inventory so that supply continuity is maintained. This project is moving forward in careful coordination with our vendors and distribution partners, every one of whom understands the special demands of medical device manufacturing, and in particular the regulatory approvals that are required. We expect that the temporary working capital investment — which weighed on our second quarter cash flow and will weigh further on our third quarter cash flow — will allow us to hit our 2026 revenue guidance of $51 million to $53 million. Cash flow from operations ought to be unaffected, yet the greater deployment of working capital will lower our cash on hand through 2026, with that turning around and becoming a cash tailwind in 2027 as we draw down the elevated inventory levels and keep managing our working capital more tightly; we continue to right-size the business with discipline, and the positive cash flow we delivered in the second quarter stands as a proof point of our success and of the business's growing financial strength. I'm happy to report that, through our various cost savings initiatives, we have once again brought operating expenses down relative to the prior year period. As noted earlier, the relocation of our headquarters is underway, and the multi-year shift of production to lower-cost third-party contract manufacturers keeps moving forward; we see both becoming powerful drivers of improving gross margins ahead in 2027. We believe certain timing-related impacts that weighed on our first half 2026 performance amount to incremental revenue opportunities for the rest of the year. Our focus in the back half of the year remains on strengthening our supply chain, building inventory ahead of our manufacturing transitions, and advancing our international regulatory submissions. Now, if we look at how we did commercially during the quarter, our glaucoma business yet again posted strong growth driven by probes; rising demand and use of this higher-margin offering is a promising sign of greater uptake of our G6 platform, which shows physicians are increasingly embracing our technology. Within retina, we ran into several market forces and operational execution difficulties that weighed on commercial activity over the quarter. We're working hard to tackle these issues and stay committed to tightening execution, lifting performance, and setting the retina business up for durable, profitable growth. Revenue overall in the quarter came to $12.6 million. Cyclo-G6 probe volume climbed about 35% versus a year earlier, while revenue from the G6 product family grew 19%, which directly mirrors growing physician adoption of our non-incisional approach along with higher utilization of the G6 platform. It's encouraging how broad this growth was, since it originated in each region where we do business. The year-over-year revenue drop across our whole business stemmed entirely from retina and from a group of temporary commercial transition and regulatory-related factors abroad, and not from any shift in underlying demand for our products. Beginning with glaucoma for the quarter, Cyclo-G6 probe volume came to 17,700 units, up 35% from 13,100 units sold a year earlier. Across the U.S., three initiatives are fueling robust growth: customer targeting with MedScout, LCD tailwinds, and higher ASPs. Our leading growth driver in glaucoma for the quarter remained greater utilization of the G6 platform, with especially strong momentum in probe volumes. Thanks to MedScout, we've grown far more precise in how we spot and connect with physicians who have the best chance to boost utilization. We're zeroing in on two main segments: current G6 accounts with moderate utilization, where procedure volume could rise, and high-volume glaucoma practices that haven't yet brought MicroPulse therapy into their treatment protocols. In both segments, our commercial team works straight with physicians via education centered on suitable patient selection, clinical outcomes, and how effective and versatile the procedure is. This focused strategy is helping us shift past merely placing systems and toward generating more utilization from the installed base. We're also still seeing tailwinds from the Medicare LCDs put in place last year, which have encouraged wider consideration of MicroPulse therapy throughout the glaucoma treatment continuum. Our commercial organization treats these reimbursement developments as a key educational opening, partnering with physicians to emphasize the procedure's capacity to reduce IOP while offering a non-incisional, repeatable treatment choice. We think this mix of clinical education, reimbursement support, and expanding physician experience is helping broaden the role of G6 therapy within glaucoma treatment pathways. The third factor behind glaucoma revenue growth was yet another rise in U.S. average selling prices for both probes and systems. Ongoing gains in ASPs mirror the value physicians see in MicroPulse therapy and the clinical utility of the G6 platform. What matters here is that as we push utilization higher across the installed base, we see an appealing basis for ongoing expansion in the glaucoma segment, coming from the mix of larger probe volumes plus better ASPs. Turning to systems, 18 Cyclo-G6 units went out in the quarter, compared with 35 a year earlier; that decline came mostly from how orders were timed in Europe, Middle East, and Africa, along with persistent competitive headwinds affecting new console placements in our GmbH business. Now for the international glaucoma business: in Europe, Middle East, and Africa, our U.K. registry is moving along well, and the clinical community keeps engaging strongly. We think the data coming out of that registry will mark an important step toward securing wider reimbursement for MicroPulse therapy in the U.K. Broader reimbursement would mean better patient access, more physicians adopting it, and, as time passes, higher utilization of the installed G6 base plus larger probe volumes. We think that puts us in a good spot for ongoing growth in the U.K. and wider adoption throughout the region. In GmbH, Germany and Austria operations did well once more, since we keep winning back business that our former distributor used to handle. The biggest weak area in the region is still G6 console sales, where rivalry for new console placements continues. In Asia, our distributor partner started building inventory before the upcoming business transition in Japan, which lifted purchases of MicroPulse P3 probes, EndoProbes, and PASCAL systems. In Latin America and Canada, G6 probe sales stayed level, mainly because of Brazil, where our distributor built up inventory ahead of our upcoming business.
When it comes to Canada, the commercial emphasis and the programs we put in place during the prior quarter are producing steady outcomes. All told, growth in glaucoma was widespread throughout our international markets in this period, underscoring just how resilient our value proposition is on a worldwide basis. Moving on to the retina portfolio, our approach continues to rest on 3 pillars: pushing forward the PASCAL upgrade cycle here in the U.S., growing PASCAL's presence abroad, and obtaining regulatory approvals for our next-generation platforms, which will let us capitalize on our worldwide distribution network. We stay optimistic about what the retina business can achieve, and customer demand stayed robust. With that said, in this quarter we ran into market and operational execution dynamics that hurt sales in the period; we are working actively to address these issues and are confident that we are putting long-term fixes in place that will sharpen our execution and distributor sell-through. Since the previous earnings call, we made an important move to widen access to our retina product portfolio in the U.S., disclosing the addition of our EndoProbe handpieces to the products we already offer with EyePro GPO. Through that arrangement, we now provide more than 4,300 member practices, ambulatory surgery centers, and hospitals nationwide with preferred pricing on EndoProbe, adding to the PASCAL, IQ 532, IQ 577, OcuLight TX, and Cyclo-G6 platforms already offered via that channel; we view this as a significant broadening of the value we deliver to retina specialists and ophthalmic providers, and one more lever backing our U.S. retina business moving forward. Shifting to international retina, results overseas were uneven, and we are acting to make sure we perform commercially and operationally in a way that meets the robust demand from customers around the world; in Europe, Middle East, and Africa, we expect PASCAL to obtain MDR approval in Europe during the first half of next year. Once that certification is finished, we anticipate substantial demand. In China, sell-through took a hit from regulatory constraints along with the need for our distributor to clear out existing inventory prior to submitting further orders; we are actively moving the regulatory renewal process ahead and expect these factors to settle down across the quarters to come. In Latin America and Canada, PASCAL sales picked back up after earlier market difficulties, and we expect ongoing momentum and growth for the balance of the year. As we look toward the rest of 2026, our priorities stay centered on commercial and operational execution alongside ongoing expense management in order to generate positive cash flow from operations for the year. Consistent with these priorities, we are reaffirming our full-year revenue guidance of $51 million to $53 million. To repeat, that range leaves out revenue from the Middle East region and, on a comparable basis, represents approximately 1% to 5% pro forma growth versus 2025. The timing of international ordering significantly affected our results in this quarter; in certain markets, that creates added opportunity as previously deferred backlog moves and the product re-registration connected to our relocation is finished. Conversely, in certain areas where our channel partners submitted bigger inventory purchases during this period, we anticipate a matching drop in the following period, which reflects a degree of ongoing unevenness across various geographies worldwide. At this point, I'll pass things to Romeo so he can walk you through the financial results.
Appreciate that, Patrick, and hello everyone this afternoon. As Patrick mentioned, and as we laid out in the press release, revenue on a total basis for Q2 of 2026 came in at $12.6 million, which represents a 7% drop from the $13.6 million recorded in Q2 of 2025. The main driver of that year-over-year decrease was weaker sales of retina products, though that was partially balanced out by ongoing gains in glaucoma probe sales. Now looking at the pieces, retina product revenue landed at $6.5 million, compared with $8.0 million during the same period a year ago. As Patrick pointed out, temporary headwinds accounted for all of that drop, things like international commercial transitions and regulatory-related factors. Demand underneath, globally, for our core products stayed strong and fundamentally sound. For the Cyclo-G6 product family, total product revenue reached $3.9 million, which works out to 19% growth year-over-year against $3.3 million in the comparable quarter last year. That growth comes from higher unit volumes in both the U.S. and abroad, plus an increase in domestic ASP. Other revenue came to $2.2 million, basically unchanged from $2.2 million in Q2 of 2025. Gross profit for Q2 was $4.3 million, which equates to a gross margin of 34.2%, roughly level with $4.7 million, or 34.5%, a year earlier. The favorable impact of our higher-margin glaucoma probe was mostly canceled out by weaker retina systems margins and several cost pressures during the quarter. We still see our shift toward lower-cost third-party contract manufacturers as a significant catalyst for gross margin gains through the rest of this year and into 2027. Operating expenses came in at $5.3 million for Q2 of 2026, a decrease of $0.3 million, or 5%, from $5.6 million in Q2 of 2025. That decrease came largely from reduced general and administrative expenses, reflecting savings tied to the administrative function transfer initiative we've talked about in earlier periods. That initiative is still moving forward, and we're on track to finish relocating our headquarters later this year. Net loss was $1.3 million, or $0.07 per share, for Q2 of 2026, versus a net loss of $1.0 million, or $0.06 per share, during the same period last year. Non-GAAP adjusted EBITDA for Q2 of 2026 was a loss of $0.4 million for the quarter, compared with non-GAAP adjusted EBITDA income of $21,000 in Q2 of 2025. We closed the quarter with cash and cash equivalents totaling $4.7 million as of July 4, 2026, which is $0.1 million higher than April 4, 2026. As Patrick stressed, we were glad to generate positive cash flow this quarter, a notable sign of the financial discipline now steering the business, delivered through tight cost control and better working capital, even while we build safety stock for certain distributors ahead of our relocation. Over the remaining quarters, we expect quarterly cash generation to grow sequentially as we sell through inventory and gather receivables on higher revenue. That said, we do anticipate a temporary reinvestment of operating cash flow into advanced inventory procurement. This proactive inventory cushion locks down our global supply chain and safeguards the top-line revenue streams coming from distributors as we make the move to our new production facility. Now for guidance, we are reaffirming what we said for 2026. Revenue is still expected to land somewhere between $51 million and $53 million. Keep in mind that because of the market disruption tied to the ongoing conflict in the Middle East, that outlook leaves out revenue from that region. If you look at it on a pro forma basis that strips out 2020, 2025 Middle East revenue, the guide implies 2026 growth of 1% to 5% over 2025; we are also reiterating our expectation for adjusted operating expenses, which include depreciation and amortization and stock compensation, to be in the range of $19 million to $19.5 million for the full year of 2026. I will now pass the call back to Patrick for his closing remarks.
Appreciate that, Romeo. When I think about what we accomplished in Q2, what stands out is how broadly our glaucoma business kept performing strongly, and even more so, the fact that we've shown we can steer this company all the way to generating positive cash flow. The discipline we apply to costs continues to show up as better cash generation, and neither our manufacturing transition nor the relocation of our headquarters has fallen off track — both should bring meaningful extra margin gains as 2026 progresses. As for our priorities for 2026, they haven't shifted: we want to drive greater G6 utilization and adoption around the world, obtain international regulatory clearances that let our retina systems reach new geographies, and finish shifting production to contract manufacturers with lower costs so gross margin goes up. What we've built stands on solid ground. There's a clear route to lasting profitability, and the road ahead has us excited. Thank you for sticking with IRIDEX, and we can't wait to update you on how things are going when we speak again next quarter. At this point, I'll hand things over to the operator so we can take questions.
Just a few things I wanted to ask. To start with retina, it seems there are many pieces in motion both here at home and abroad. What I want to know is whether you see retina increasing compared with last year when looking at the entire year, which would mean a fairly large lift is needed across the back half? So setting the whole year aside, would you expect the latter six months of '26 to come in above the latter six months of '25?
Correct. Scott, thanks for asking; across the back half of the year, our expectation for retina is growth in the low single digits. A number of meaningful tailwinds are in play as we move forward with regulatory clearances outside the U.S. That should expand the market we can reach and lift results overall, especially for PASCAL, our flagship offering. And within the U.S., over the back half, we anticipate building momentum as the American Academy of Ophthalmology meeting approaches. Our plan is to roll out the annual promotion programs, which are quite helpful for capital equipment sales and genuinely fuel customer engagement after that meeting; those are the tailwinds, some tailwinds, that we see. Headwinds came from ongoing disruption in the Middle East. We saw certain sell-through delays in China stemming from stocking orders placed earlier because of the tariffs, plus simply handling our relocation and the inventory management that followed for the blackout periods tied to our headquarters move. Yet again, our expectation is that the back half produces low single-digit growth for retina.
All right, and should we anticipate — you know, in past years the fourth quarter has been far more robust compared with the third — should we anticipate the same situation in this year too?
Yeah, absolutely. Generally, it's our biggest one by a good margin, the fourth quarter.
All right. Turning to glaucoma — 17,700 probes was a big number for Q3, far and away the strongest of the last five or six quarters. Do you suspect any stocking up happened at your customers? In other words, ought we to anticipate a return to more usual amounts, or does this represent a permanent shift?
No, I wouldn't describe it as a permanent shift. For the back half of the year, our expectation is growth in the low double digits. Once you strip out — well, Japan did put in certain orders, larger ones, to handle the blackout period. And not only Japan — Europe had a bit of that as well, to get through those blackout periods. Strip that out, though, and growth still came in above 15%, and getting that in the back half of the year would leave us quite pleased. So there was a bit of what I'd term lumpiness from the pre-orders tied to covering the blackout period, yet excluding those, growth remained genuinely strong.
All right, and then one last thing — the 18 systems that were sold, that figure came in somewhat lower. Should we anticipate a rebound to a greater level during the back half of the year? In terms of a go-forward figure, how are we to interpret that 18?
Toward the later portion of the year, we think it will be significantly greater. Once more, our biggest quarter is Q4, and system sales are included in that, so as we continue ahead, those figures ought to be bigger. We experienced some sluggishness in Europe, Middle East, and Africa — you know, we're awaiting approval, and once the U.K. registry grants that approval for reimbursement, it will assist in lifting certain sales there — so that set us back during this quarter, but over the second half of the year, we do anticipate those figures will rise. And thank you all for being with us.
We appreciate everyone being with us once more. That brings today's conference call to a close. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IRIDEX Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IRIDEX Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.